The present disclosure relates to a handheld diabetes managing device and, more particularly, relates to a handheld diabetes managing device with a light system for enhanced illumination of a test strip and an area proximate to the test strip.
Diabetes mellitus, often referred to as diabetes, is a chronic condition in which a person has elevated blood glucose levels that result from defects in the body's ability to produce and/or use insulin. Diabetes is managed primarily by determining and controlling the level of glucose in the bloodstream.
Blood glucose diagnostic information is typically obtained from a capillary blood sample with a lancing device and is then measured with a handheld blood glucose meter. There are times in which the diabetes patient may wish to perform personal glucose testing in low light conditions. For instance, the patient may want to perform the test in a dark or poorly lit room. Because the test requires a certain amount of precision (e.g., proper placement of a blood droplet on the dosing area of a test strip), it can be difficult to complete the test in such conditions. Known handheld diabetes management devices providing illumination in such situations are not capable of providing all of the capabilities of illuminating the insertion location of a test strip, and a dosing location on the test strip.
Further, known handheld diabetes management devices are limited in areas that can support a light source for such illumination. Often light must be directed through an interior of the handheld diabetes management device in a light pipe before illuminating the test strip. The light pipe adds size, weight and cost to the device.
This section provides background information related to the present disclosure which is not necessarily prior art.
This section provides a general summary of the disclosure, and is not a comprehensive disclosure of its full scope or all of its features.
A handheld diabetes management device for providing enhanced illumination on a dosing area of a diabetes test element is disclosed. The diabetes management device includes a housing receiving a test strip through a port in the housing. A circuit board is mounted inside the housing and faces an opposing top surface of the test strip. A measurement module is mounted to the circuit board and is cooperatively operable with the test strip inserted into the port to measure a sample of fluid residing on the test strip. A light source is mounted on the circuit board and is operable to emit light substantially perpendicular to the opposing top surface of the test strip. The light source projects the light along an optical axis substantially perpendicular to the opposing top surface of the test strip and illuminates an area surrounding a dosing end of the test strip.
According to other aspects, a handheld diabetes management device includes a housing. A strip connector is positioned within the housing and is configured to receive a test element. A circuit board having a first side and a second side is mounted inside the housing. A measurement module is positioned proximate to the strip connector and is mounted to the first side. A light source is mounted on the first side and is operable to emit photons substantially perpendicular to the top surface of the test element. A first layer of the test element receives and transmits the photons along a length of the test element, discharging the photons at a dosing area.
Moreover, a method of providing test strip illumination is disclosed. The method includes slitting a sheet of material to form first and second ends of a test strip, such that a light path is not altered when passed through the first or second end; cutting the slit portions of material to form first and second sides of the test strip, such that the sides include micro serrations; passing a light beam through a top side of the test strip at an optical axis perpendicular the top side; and transmitting the light beam through the test strip to illuminate an area surrounding a dosing area of the test strip, wherein the first and second ends create a constructive interference of the light beam in a length-wise direction and the first and second sides create a destructive interference of the light beam in a width-wise direction, channeling the light beam through a center of the test strip and toward the dosing area.
Further areas of applicability will become apparent from the description provided herein. The description and specific examples in this summary are intended for purposes of illustration only and are not intended to limit the scope of the present disclosure.
The drawings described herein are for illustrative purposes only of selected embodiments and not all possible implementations, and are not intended to limit the scope of the present disclosure.
Corresponding reference numerals indicate corresponding parts throughout the several views of the drawings.
Example embodiments will now be described more fully with reference to the accompanying drawings.
Referring initially to
Device 10 may be used for analyzing a body fluid disposed on edge/dosing area 34. For instance, as will be discussed, test strip 30 can be a disposable glucose test strip of the type discussed below. In the example embodiment, a droplet of blood is applied from dose/sample 38 while test strip 30 is inserted within device 10, and device 10 analyzes the droplet to detect a blood glucose level therein. In an alternative embodiment, the body fluid is applied from dose/sample 38 while test strip 30 is removed from device 10 and then inserted into device 10 for analysis. It will be appreciated that while device 10 analyzes blood in the example embodiment, in alternative embodiments, device 10 could be used for analyzing any other suitable characteristic of any other body fluid without departing from the scope of the present disclosure.
Referring specifically to
Measurement engine 54 cooperatively interacts with test strip 30 inserted into access port 22 to determine the glucose measure from sample 38 on test strip 30. Measurement engine 54 may include calibration information for test strips 30 being read by device 10. Measurement engine 54 may refer to, be part of, or include, an application Specific Integrated Circuit (ASIC); an electronic circuit; a combinational logic circuit; a field programmable gate array (FPGA); a processor (shared, dedicated, or group) that executes code; other suitable components that provide the described functionality; or a combination of some or all of the above. Measurement engine 54 may further include memory that stores code executed by the processor, where code, as used above, may include software, firmware, and/or microcode, and may refer to programs, routines, functions, classes, and/or objects.
Processing subsystem 58 is configured to receive the glucose measures from measurement engine 54 which may in turn be stored in memory by processing subsystem 58. Glucose measures may also be displayed by processing subsystem 58 on display 18. The user can interact with device 10 using various user interface components, such as buttons, switches, a speaker, a microphone, USB port, etc. Each of these components is interfaced with processing subsystem 58. In an exemplary embodiment, processing subsystem 58 includes a microprocessor 66 and one or more volatile and/or non-volatile memories 70, although other implementations are envisioned for the processing subsystem.
Processing subsystem 58 is also interfaced with communication subsystem 62. In an exemplary embodiment, communication subsystem 62 includes a wireless transceiver 74. Wireless transceiver 74 operates to communicate the glucose measures and other data wirelessly via a data link to a remote device physically separated from device 10. Communication subsystem 62 can also include an antenna, microcontroller, voltage and power control circuits and a flash memory device. Although a few primary components of device 10 are discussed herein, it is readily understood that other components (e.g., a power source) may be needed to implement device 10.
Referring now to
In the example embodiment, a light source 90 is mounted to circuit board 78. Light source 90 can be of any suitable type, such as a light emitting diode (LED). Light source 90 is mounted to the same side of circuit board 78 as the measurement engine 54 (i.e., bottom side 86 of circuit board 78). In an alternative embodiment, light source 90 may be mounted to top side 82 of circuit board 78. In still another embodiment, light source 90 may be mounted separate from circuit board 78 and connected to circuit board 78.
In the example embodiment, light source 90 is positioned approximately 0.0001 and 0.001 inches from a first surface 94 of test strip 30 when test strip 30 is in the testing position. The closer light source 90 is positioned to first surface 94, the better the transmission of light through test strip 30. In alternative embodiments, light source 90 may be in contact with first surface 94. Since light source 90 is positioned to emit light directly on to test strip 30, no alignment of light source 90 with respect to test strip 30 is necessary. Further, there is no need for additional apparatuses to direct light to a location on test strip 30.
Measurement engine 54 can be of a known type for analyzing body fluid applied to test strip 30 as discussed above. Measurement engine 54 can be operably mounted to circuit board 78 and can communicate with access port 22. As such, when test strip 30 is inserted within access port 22 and body fluid is applied, measurement engine 54 can perform the predetermined analysis. Moreover, measurement engine 54 may include associated software and logic for performing and controlling the analysis of the body fluid.
During operation, as shown in
At 112, first surface 94 receives the light traveling in direction E. In some embodiments, first surface 94 may scatter the light from the original light beam. In other embodiments, first surface 94 may alter the part of the light from direction E. Test strip 30 receives the light and transmits the light in a first direction D1 toward a reflecting surface 114. At 116, the light reflects from the reflecting surface 120 and is redirected toward a second direction D2 (shown in
Referring specifically to
Longitudinal transparent layer 132 is a clear, transparent, or translucent, layer and may be of any material that is clear or transparent. For example, first layer 132 may be a polyethylene layer, a glass layer, or any other material. First layer 132 may also have low reflectivity. In some embodiments, second layer 136 may be of a similar material and may act as a spacer between first layer 132 and third layer 140. In alternative embodiments, second layer 136 may be an adhesive for securing first layer 132 to third layer 140. Further, in still other embodiments, second layer 136 may include a reagent. Third layer 140 may contain a metal for electrodes and a reagent. In the example embodiment, at least one of second layer 136 and third layer 140 must be of an opaque material. The at least one layer of the opaque material may also be reflective to guide the light beam through test strip 30.
Now referring to
While, in the example embodiment, longitudinal transparent layer 132 is described as being a clear transparent layer, in alternative embodiments, longitudinal transparent layer 132 could also include a polarizing film. When the longitudinal transparent layer 132 is polarized, the light is not dispersed within the layer, but, instead, travels in a more columnized form through the length of test strip 30, resulting in less light being dispersed along test strip 30 and more light exiting as light beam F.″ Further, in an alternative embodiment, dosing area 34 of test strip 30 may be of a light scattering texture to disperse the light beam.
The foregoing description of the embodiments has been provided for purposes of illustration and description. It is not intended to be exhaustive or to limit the disclosure. Individual elements or features of a particular embodiment are generally not limited to that particular embodiment, but, where applicable, are interchangeable and can be used in a selected embodiment, even if not specifically shown or described. The same may also be varied in many ways. Such variations are not to be regarded as a departure from the disclosure, and all such modifications are intended to be included within the scope of the disclosure.
Number | Name | Date | Kind |
---|---|---|---|
4288672 | Puccini | Sep 1981 | A |
4432366 | Margules | Feb 1984 | A |
5228972 | Osaka et al. | Jul 1993 | A |
5304468 | Phillips et al. | Apr 1994 | A |
5320732 | Nankai et al. | Jun 1994 | A |
5395504 | Saurer et al. | Mar 1995 | A |
5407554 | Saurer | Apr 1995 | A |
5522255 | Neel | Jun 1996 | A |
5547702 | Gleisner | Aug 1996 | A |
5563042 | Phillips et al. | Oct 1996 | A |
5651869 | Yoshioka et al. | Jul 1997 | A |
5686829 | Girault | Nov 1997 | A |
5997817 | Crismore et al. | Dec 1999 | A |
6201607 | Roth et al. | Mar 2001 | B1 |
6514460 | Fendrock | Feb 2003 | B1 |
6830551 | Uchigaki et al. | Dec 2004 | B1 |
6847451 | Pugh | Jan 2005 | B2 |
7276027 | Haar et al. | Oct 2007 | B2 |
7285198 | Douglas | Oct 2007 | B2 |
7867369 | Bhullar | Jan 2011 | B2 |
7991257 | Coleman | Aug 2011 | B1 |
8431408 | Lewis | Apr 2013 | B2 |
8465977 | Joseph et al. | Jun 2013 | B2 |
20030161572 | Johnck | Aug 2003 | A1 |
20030207441 | Eyster et al. | Nov 2003 | A1 |
20030211636 | Bedian | Nov 2003 | A1 |
20040032748 | Trudeau | Feb 2004 | A1 |
20040219691 | Shartle et al. | Nov 2004 | A1 |
20050009126 | Andrews et al. | Jan 2005 | A1 |
20050023137 | Bhullar et al. | Feb 2005 | A1 |
20050201897 | Zimmer et al. | Sep 2005 | A1 |
20050265094 | Harding et al. | Dec 2005 | A1 |
20050276133 | Harding et al. | Dec 2005 | A1 |
20060099108 | List et al. | May 2006 | A1 |
20060100542 | Wong et al. | May 2006 | A9 |
20060222567 | Kloepfer et al. | Oct 2006 | A1 |
20070167869 | Roe | Jul 2007 | A1 |
20070255301 | Freeman et al. | Nov 2007 | A1 |
20100021342 | Joseph | Jan 2010 | A1 |
20100208488 | Luo | Aug 2010 | A1 |
20110149591 | Smith | Jun 2011 | A1 |
20120095316 | Lewis | Apr 2012 | A1 |
20130105074 | Riggles | May 2013 | A1 |
20130146478 | Iyengar | Jun 2013 | A1 |
20140078772 | Gaydoul | Mar 2014 | A1 |
20140268864 | Lee | Sep 2014 | A1 |
Number | Date | Country |
---|---|---|
1146016 | Mar 1997 | CN |
198 19 407 | Nov 1998 | DE |
198 49 539 | May 2000 | DE |
198 57 426 | Jun 2000 | DE |
101 05 549 | Aug 2002 | DE |
0 407 800 | Jan 1991 | EP |
1 199 978 | May 2002 | EP |
1 424 040 | Jun 2004 | EP |
1 918 707 | May 2008 | EP |
2 377 465 | Oct 2011 | EP |
05-164756 | Jun 1993 | JP |
816799 | Mar 2008 | KR |
WO 9216909 | Oct 1992 | WO |
WO 200108551 | Feb 2001 | WO |
WO 2005119234 | Dec 2005 | WO |
WO-2005119234 | Dec 2005 | WO |
WO 2012003306 | Jan 2012 | WO |
Entry |
---|
DE 198 19 407 A1 Machine Translation. |
DE 198 49 539 A1 Machine Translation. |
DE 198 57 426 A1 Machine Translation. |
European Patent Application No. 09 777 286.7 Office Action dated Jul. 14, 2011. |
Glucometer Elite® Diabetes Care System User Guide, Bayer Corporation, Elkhart, IN, Rev. 6/98. |
International Application No. PCT/EP2009/005233 International Preliminary Report on Patentability dated Oct. 8, 2010. |
International Application No. PCT/EP2009/005233 International Search Report and Written Opinion dated Oct. 22, 2010. |
International Patent Application No. PCT/EP03/13298 International Search Report dated Apr. 10, 2004. |
JP 05-164756 A English Language Abstract. |
U.S. Appl. No. 10/008,788, “Fourth Supplemental Information Disclosure Statement”, dated Mar. 8, 2007. |
Number | Date | Country | |
---|---|---|---|
20150338349 A1 | Nov 2015 | US |